ChemPartner PharmaTech Co.,Ltd. Stock

Equities

300149

CNE100000Y27

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-07 pm EDT 5-day change 1st Jan Change
5.55 CNY +3.16% Intraday chart for ChemPartner PharmaTech Co.,Ltd. +5.31% -27.45%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2022 1.33B 184M Sales 2023 1.14B 158M Capitalization 3.81B 527M
Net income 2022 379M 52.45M Net income 2023 -908M -126M EV / Sales 2022 4.06 x
Net Debt 2022 205M 28.31M Net Debt 2023 286M 39.57M EV / Sales 2023 3.6 x
P/E ratio 2022
13.7 x
P/E ratio 2023
-4.2 x
Employees 2,072
Yield 2022 *
-
Yield 2023
-
Free-Float 23.15%
More Fundamentals * Assessed data
Dynamic Chart
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Chempartner Pharmatech Announces Resolutions of the The First Extraordinary General Meeting of Shareholders 2024. CI
MEGA STAR CENTRE LIMITED Announces Nominee to the Board of Chempartner Pharmatech. CI
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
ChemPartner PharmaTech CFO Steps Down MT
Chempartner Pharmatech Co., Ltd.(XSEC:300149) added to S&P Global BMI Index CI
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chempartner Pharmatech Co., Ltd.(XSEC:300149) dropped from S&P Global BMI Index CI
Chinese Shares End Mixed; ChemPartner Falls 6% as Chairman Assumes CEO Role MT
ChemPartner PharmaTech Appoints Chairman as CEO; Shares Rise 4% MT
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
More news
1 day+3.16%
1 week+5.31%
Current month+5.31%
1 month+3.16%
3 months+28.77%
6 months-38.67%
Current year-27.45%
More quotes
1 week
5.21
Extreme 5.21
5.65
1 month
4.13
Extreme 4.13
5.65
Current year
3.68
Extreme 3.68
7.65
1 year
3.68
Extreme 3.68
9.74
3 years
3.68
Extreme 3.68
20.82
5 years
3.68
Extreme 3.68
24.89
10 years
3.68
Extreme 3.68
28.55
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 23-02-07
Director of Finance/CFO 45 23-10-07
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 53 18-07-31
Director/Board Member 62 20-10-11
Director/Board Member 54 21-08-22
More insiders
Date Price Change Volume
24-05-08 5.55 +3.16% 13,886,860
24-05-07 5.38 +1.51% 11,251,430
24-05-06 5.3 +0.57% 12,929,350
24-04-30 5.27 +1.74% 9,117,744

End-of-day quote Shenzhen S.E., May 07, 2024

More quotes
ChemPartner PharmaTech Co Ltd, formerly Quantum Hi-tech China Biological Co Ltd, is a China-based company principally engaged in the research, development, production, and sales of fructooligosaccharides and other prebiotics. The Company's main products include fructooligosaccharides and galactooligosaccharides. The Company owns brands names of FOS and GOS. The Company's products are mainly used in nutrition and health products, dairy products, beverages, baked goods, functional candy and snack foods. The Company distributes its products mainly in domestic market, with South China as its main market.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300149 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW